NERV · NASDAQ · Biotechnology

Minerva Neurosciences (NERV)

Develops roluperidone for negative symptoms of schizophrenia through a confirmatory Phase 3 trial.

$3.61
vs last close−0.20 (−5.25%)
  1. What Makes Minerva Neurosciences (NERV) a New Buy Stock

    Zacks Investment Research